Performance Measures

AGA's Role

AGA has been a leader in performance measurement since 2006 and has developed measures for several digestive health conditions and clinical topics including: colorectal cancer screening and surveillance (CRC), gastroesophageal reflux disease (GERD), hepatitis C (HCV) and other liver diseases, and inflammatory bowel disease (IBD).

The AGA Institute Quality Measures Committee provides clinical and methodological expertise and oversight for the development, specification, maintenance and testing of AGA's performance measures.

2017 AGA Performance Measures

Colorectal Cancer Screening and Surveillance

 

GERD

 

Hepatitis C / Liver Diseases

Patients with Cirrhosis, Surveillance for Developing Hepatocelluar Carcinoma (HCC) (In Development)

 

IBD

Inflammatory Bowel Disease: Postoperative Endoscopic Monitoring at 6 to 12 Months After Surgical Resection in Patients with Surgically Induced Remission of Crohn’s Disease NOT Receiving Pharmacological Prophylaxis (In Development)

Inflammatory Bowel Disease: Postoperative Endoscopic Monitoring at 6 to 12 Months after Surgical Resection in Patients with Crohn’s Disease (In Development)

 

Inactive / presently unimplemented AGA performance measures